Medigene Dirección

Dirección controles de criterios 1/4

El CEO de Medigene es Selwyn Ho, nombrado en Jul 2022, tiene una permanencia de 2.17 años. posee directamente un 0.42% de las acciones de la empresa, con un valor de €124.75K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 7.1 años, respectivamente.

Información clave

Selwyn Ho

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.2yrs
Participación del CEO	0.4%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Selwyn Ho en comparación con los beneficios de Medigene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-€16m
Mar 31 2024	n/a	n/a	-€16m
Dec 31 2023	n/a	n/a	-€16m
Sep 30 2023	n/a	n/a	-€23m
Jun 30 2023	n/a	n/a	-€29m
Mar 31 2023	n/a	n/a	-€19m
Dec 31 2022	€612k	€157k	-€8m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Selwyn es razonable en comparación con empresas de tamaño similar en el mercado UK.

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Selwyn con los resultados de la empresa.

CEO

Selwyn Ho (53 yo)

2.2yrs

Permanencia

€612,472

Compensación

Dr. Selwyn Ho, MBBS, serves as Chief Executive Officer & Chairman of the Executive Management Board at Medigene AG since July 25, 2022. He served as Chief Business Officer at Connect Biopharma Holdings Lim...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Selwyn Ho	CEO & Chairman of Executive Management Board	2.2yrs	€612.47k	0.42% € 124.8k
Dolores Schendel	Chief Scientific Officer	10.3yrs	€624.00k	sin datos
Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	no data	€20.00k	sin datos
Birger Kohlert	Chief Financial Officer	no data	sin datos	sin datos
Pamela Keck	Vice President of Investor Relations & Corporate Communications	1.5yrs	sin datos	sin datos
Kirsty Crame	VP and Head of Clinical Research & Development	1.5yrs	sin datos	sin datos

1.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0QGJ no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	7.1yrs	€20.00k	sin datos
Anthony Man	Independent Member of the Supervisory Board	3.8yrs	€21.00k	sin datos
Antoinette Hiebeler-Hasner	Independent Deputy Chairwomen of the Supervisory Board	8.1yrs	€36.00k	sin datos
Gerd Zettlmeissl	Independent Chairman of the Supervisory Board	7.3yrs	€46.00k	sin datos
Ronald Scott	Independent Member of the Supervisory Board	7.3yrs	€24.00k	sin datos
Frank Mathias	Independent Member of the Supervisory Board	6.3yrs	€30.00k	0.071% € 21.2k
Peter Krammer	Member of Scientific Advisory Board	7.1yrs	sin datos	sin datos
Lawrence Samelson	Member of Scientific Advisory Board	7.1yrs	sin datos	sin datos
Micha Drukker	Member of Scientific Advisory Board	7.1yrs	sin datos	sin datos
Freda Stevenson	Member of Scientific Advisory Board	7.1yrs	sin datos	sin datos
Jolanda de Vries	Member of Scientific Advisory Board	7.1yrs	sin datos	sin datos

7.1yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 0QGJ se considera experimentada (7.1 años de antigüedad promedio).

Medigene Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Executive Changes

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Recent updates

Medigene AG Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities At Cell 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.17 loss in 2Q 2023)

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings released: €0.66 loss per share (vs €0.34 loss in FY 2022)

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Forecast to breakeven in 2022

Medigene Confirms Revenue Guidance for 2021

Medigene AG Provides Earnings Guidance for the Year 2021

Advisor has left the company

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

New 90-day high: €4.53

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial

Earnings released

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad